. Surprisingly, we observed that p53 activation modulates ferroptotic responses without apparent effects on GPX4 function. Instead, ALOX12 inactivation diminishes p53-mediated ferroptosis induced by reactive oxygen species stress and abrogates p53-dependent inhibition of tumour growth in xenograft models, suggesting that ALOX12 is critical for p53-mediated ferroptosis. The ALOX12 gene resides on human chromosome 17p13.1, a hotspot of monoallelic deletion in human cancers. Loss of one Alox12 allele is sufficient to accelerate tumorigenesis in Eμ-Myc lymphoma models. Moreover, ALOX12 missense mutations from human cancers abrogate its ability to oxygenate polyunsaturated fatty acids and to induce p53-mediated ferroptosis. Notably, ALOX12 is dispensable for ferroptosis induced by erastin or GPX4 inhibitors; conversely, ACSL4 is required for ferroptosis upon GPX4 inhibition but dispensable for p53-mediated ferroptosis. Thus, our study identifies an ALOX12-mediated, ACSL4-independent ferroptosis pathway that is critical for p53-dependent tumour suppression. ) as indicated for 24 h. The experiments were repeated twice, independently, with similar results. c, U2OS cells transfected with control or ALOX12 siRNA were pre-incubated with Nutlin (10 µM) for 12 h, and then the cells were treated with Nutlin (10 µM) and TBH (300 µM) as indicated for 8 h. Mean ± s.d. is shown; n = 3 independent experiments. d, Western blot analysis of U2OS cells transfected with control or ALOX12 siRNA and then treated with Nutlin (10 µM) as indicated for 48 h. The experiments were repeated twice, independently, with similar results. e, Representative phase-contrast images of U2OS ctrl CRISPR (top panels) and ALOX12 CRISPR (bottom panels) cells pre-incubated with Nutlin (10 µM) for 12 h were treated with TBH (300 µM) and Nutlin (10 µM) as indicated for 8 h. Scale bars, 100 µm. The experiments were repeated twice, independently, with similar results. f, U2OS control, ALOX12 and p53 CRISPR cells pre-incubated with Nutlin (10 µM) for 12 h were treated with TBH (300 µM), Nutlin (10 µM) and Ferr-1 (2 µM) as indicated for 8 h. Mean ± s.d. is shown; n = 3 independent experiments. g, Western blot analysis of U2OS control and ALOX12 CRISPR cells treated with Nutlin (10 µM) as indicated for 48 h. The experiments were repeated twice, independently, with similar results. All P values (a,c,f) were calculated using two-tailed unpaired Student's t-test. Detailed statistical tests are described in the Methods. Scanned images of unprocessed blots are shown in Supplementary Fig. 9 . Raw data are provided in Supplementary 
A lthough p53-mediated cell-cycle arrest, senescence and apoptosis serve as critical barriers to cancer development, accumulating evidence reveals that p53-mediated metabolic regulation also promotes tumour suppression 1 . We and others have recently found that p53 plays an important role in modulating ferroptotic responses through its metabolic targets [2] [3] [4] [5] [6] . Nevertheless, the molecular factors that mediate p53-dependent ferroptosis have not been delineated and the mechanism by which this ferroptosis pathway is regulated remains unclear. Ferroptosis is a regulated form of cell death driven by excess accumulation of lipid peroxides [7] [8] [9] [10] . Lipid peroxides are normally eliminated by glutathione peroxidase 4 (GPX4) and its co-factor glutathione (GSH), which convert lipid hydroperoxides to non-toxic lipid alcohols [8] [9] [10] . It is well established that ferroptosis is primarily controlled by GPX4 (refs. [11] [12] [13] [14] [15] [16] [17] [18] [19] ). Although inactivation of p53 expression can partially reduce erastin-initiated cell death in certain cell types [2] [3] [4] [5] [6] , the ferroptotic responses induced by erastin or GPX4 inhibitors are not dependent on p53 status 4 . Thus, it remains unclear whether p53-dependent ferroptosis acts through modulation of GPX4 function.
Results
Identification of ALOX12 as an essential factor of p53-dependent ferroptosis. In our previous study, we established a ferroptosis assay that requires both p53 activation and reactive oxygen species (ROS)-induced stress (see Methods) 3 . Indeed, the cell death induced by low levels of tert-Butyl hydroperoxide (TBH), a common ROS generator, is apparently p53 dependent and can be specifically inhibited by the ferroptosis inhibitor ferrostatin-1 (Ferr-1), but not by the inhibitors of other cell death pathways such as apoptosis, autophagy or necroptosis 3 . As ferroptotic cell death is tightly regulated in response to oxidative stress in vivo 8 , we reasoned that this type of ferroptosis would better reflect p53 function during an oxidative stress response.
In addition to GPX4-mediated neutralization of lipid peroxidation [11] [12] [13] [14] [15] [16] [17] [18] , the levels of cellular lipid peroxides can be induced enzymatically by the lipoxygenases. The mammalian lipoxygenase family consists of six isoforms (ALOXE3, ALOX5, ALOX12, ALOX12B, ALOX15 and ALOX15B) ( Supplementary Fig. 1a ) with differing substrate specificities 8, 10, 19 . To ascertain whether any of these lipoxygenases are required for p53-mediated ferroptosis, we performed an RNA interference (RNAi)-mediated loss-of-function screen to test whether depletion of individual isoforms affects p53-dependent ferroptosis. Quantitative PCR analyses confirmed that the expression of each of the six lipoxygenase isoforms was individually abrogated by RNAi-mediated depletion ( Supplementary Fig. 1b ). As expected, high levels of p53-mediated ferroptosis upon ROS-induced stress were detected in TBH-treated p53 3KR H1299 cells transfected with control short interfering RNAs (siRNAs). However, ferroptosis was significantly and specifically blocked by RNAi-mediated depletion of ALOX12, but not by any of the other five lipoxygenases (Fig. 1a) . Western blot analysis revealed that ALOX12 depletion had no effect on either p53 levels or p53-mediated downregulation of the cystine/ glutamate transporter SLC7A11 (Fig. 1b) .
Activation of p53 can be readily induced by Nutlin, a smallmolecular inhibitor of MDM2. Although in most human cancer cells, Nutlin-mediated p53 activation induces reversible cell-cycle arrest but not cell death, we previously showed that U2OS cells undergo p53-dependent, ROS stress-induced ferroptosis upon combined treatment with both Nutlin and TBH 3 . Again, although ALOX12 depletion had no obvious effect on p53 levels or expression of its transcriptional targets (for example, SLC7A11, MDM2 and p21) (Fig. 1d ), p53-mediated ferroptosis was largely abrogated (Fig. 1c) . To further validate the role of ALOX12 in p53-mediated ferroptosis, we used clustered regularly interspaced short palindromic repeats (CRISPR)-CRISPR-associated protein 9 (Cas9) technology ) and TBH (40 µM) as indicated for 8 h. Mean ± s.d. is shown; n = 3 independent experiments. b, Western blot analysis of H1299 Tet-on p53 3KR cells transfected with control or ALOX12 siRNA (si) and then treated with doxycycline (0.5 µg ml ) as indicated for 24 h. The experiments were repeated twice, independently, with similar results. c, U2OS cells transfected with control or ALOX12 siRNA were pre-incubated with Nutlin (10 µM) for 12 h, and then the cells were treated with Nutlin (10 µM) and TBH (300 µM) as indicated for 8 h. Mean ± s.d. is shown; n = 3 independent experiments. d, Western blot analysis of U2OS cells transfected with control or ALOX12 siRNA and then treated with Nutlin (10 µM) as indicated for 48 h. The experiments were repeated twice, independently, with similar results. e, Representative phase-contrast images of U2OS ctrl CRISPR (top panels) and ALOX12 CRISPR (bottom panels) cells pre-incubated with Nutlin (10 µM) for 12 h were treated with TBH (300 µM) and Nutlin (10 µM) as indicated for 8 h. Scale bars, 100 µm. The experiments were repeated twice, independently, with similar results. f, U2OS control, ALOX12 and p53 CRISPR cells pre-incubated with Nutlin (10 µM) for 12 h were treated with TBH (300 µM), Nutlin (10 µM) and Ferr-1 (2 µM) as indicated for 8 h. Mean ± s.d. is shown; n = 3 independent experiments. g, Western blot analysis of U2OS control and ALOX12 CRISPR cells treated with Nutlin (10 µM) as indicated for 48 h. The experiments were repeated twice, independently, with similar results. All P values (a,c,f) were calculated using two-tailed unpaired Student's t-test. Detailed statistical tests are described in the Methods. Scanned images of unprocessed blots are shown in Supplementary Fig. 9 . Raw data are provided in Supplementary Table 1 .
ALOX12 is required for p53-mediated tumour suppression through a distinct ferroptosis pathway
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NATure CeLL BIOLOGy to generate ALOX12-knockout subclones of U2OS cells. Indeed, ferroptosis was suppressed in ALOX12-knockout U2OS cells (Fig. 1e,f and Supplementary Fig. 1c-e) . Taken together, these data indicate that ALOX12 is required for p53-dependent ferroptosis.
GPX4 inhibition is not required for p53-mediated ferroptosis upon ROS stress. Interestingly, a systematic genome-wide screen failed to identify any lipoxygenase enzyme(s) required for ferroptosis induced by GPX4 inhibitors or erastin 20 . Thus, our finding that ALOX12 is specifically required for p53-mediated ferroptosis suppression is surprising and suggests that p53-mediated ferroptosis may act through a different mechanism. Lipid peroxides are normally eliminated by GPX4 and its co-factor GSH and ferroptosis can be induced by pharmacological agents including GPX4 enzymatic inhibitors and erastin, which induces GSH depletion and consequent GPX4 inactivation. To this end, we first examined the ratio of GSH/GSSG and the levels of GSH upon p53 activation. As shown in Fig. 2a,b , the ratio of reductive GSH to oxidative GSSG and the levels of GSH were dramatically reduced upon erastin treatment; conversely, following p53 activation by treatment with Nutlin, no obvious effect was detected. Consistent with these observations, activation of p53 by Nutlin treatment failed to suppress GSH peroxidase activity ( Supplementary Fig. 2a ) and had no obvious effect on endogenous lipid peroxidation ( Supplementary  Fig. 2b,c) . Nevertheless, increasing lipid peroxidation levels were detected upon combined treatment with both Nutlin and TBH ( Supplementary Fig. 2b,c) .
To further support this notion, we examined whether p53 activation has any effect on GPX4-mediated activity of endogenous lipid peroxidation levels. To this end, we first established GPX4-null p53 tetracycline (Tet)-on H1299 cells by CRISPR-mediated knockout (Fig. 2c) and then analysed the levels of endogenous lipid peroxidation by flow cytometry with C11-BODIPY staining. As shown in Fig. 2d , high levels of endogenous lipid peroxidation were detected in the GPX4-null cells, whereas upon GPX4 expression ectopically, the levels of lipid peroxidation were reduced dramatically (also see Supplementary Fig. 2d,e) . Thus, the drastic reduction of lipid peroxidation levels represents the activity of GPX4 on endogenous lipid peroxidation. As expected, treatment with the known GPX4 inhibitor RSL-3 largely abrogated the effects on lipid peroxidation reduction induced by GPX4 in those cells; however, activation of p53 failed to induce any obvious effect (Fig. 2d) . Taken together, these data indicate that p53-dependent activation of ferroptosis may act through a distinct pathway, independent of GPX4 modulation.
Inactivation of ALOX12 abrogates p53-mediated tumour growth suppression. Using xenograft tumour models in mice, we previously showed that the tumour suppression activity of p53 3KR cells, which is defective for the canonical p53 tumour suppression functions (cell-cycle arrest, apoptosis and senescence), is instead dependent on p53-mediated ferroptosis 3 . To ascertain whether ALOX12 is also required for p53-mediated tumour suppression in this setting, we first established isogenic lines of Tet-inducible p53 3KR cells in which the ALOX12 gene has or has not been knocked out by CRISPR-Cas9 technology ( Supplementary Fig. 3a) . Indeed, the levels of ferroptosis were dramatically diminished in ALOX12-knockout cells (Fig. 2e and Supplementary Fig. 3b,c) . To examine whether ALOX12 contributes to the tumour suppression activity of p53, we tested whether loss of ALOX12 expression affects tumour cell growth suppression by p53 3KR in xenograft tumour models. As expected, Tet-induced expression of p53 3KR significantly reduced tumour cell growth in this assay ( Fig. 2f and Supplementary  Fig. 3d,e) ; however, the tumour suppression effects of p53 3KR were ablated in ALOX12-knockout cells. Notably, upregulation of Ptgs2, a marker of ferroptosis 18 , was also abrogated in ALOX12-knockout cells (Fig. 2g ). These data demonstrate that ALOX12 is crucial for the tumour cell growth suppression activity of p53 in the absence of p53-mediated cell-cycle arrest, apoptosis and senescence.
Loss of one Alox12 allele is sufficient to abrogate p53-mediated ferroptosis and accelerate tumorigenesis. To further validate the role of ALOX12 in p53-mediated ferroptotic responses, we compared the sensitivity of isogenic ALOX12-mutant mouse embryonic fibroblasts (MEFs) to p53-mediated ferroptosis. As shown in Fig. 3a , ALOX12 protein levels were undetectable in homozygous (Alox12 -/-) MEFs and significantly reduced in heterozygous (Alox12 +/-) MEFs. As expected, ferroptosis was readily induced by TBH in wild-type, but not in p53-null, MEFs under the same conditions (Fig. 3b,c) , indicating that TBH-induced ferroptosis is largely p53-dependent under these conditions. Strikingly, however, cell death was not observed in either Alox12 -/-or Alox12 +/-MEFs. These data indicate that ALOX12 is haploinsufficient with respect to p53-mediated ferroptosis.
To examine whether ALOX12 also affects tumour suppression in a haploinsufficient manner, we tested whether loss of one Alox12 allele affects Myc-induced tumorigenicity in the classic Eμ-Myc lymphoma model. Previous studies have shown that Eμ-Myc mice develop late-onset B cell lymphomas between 6 and 12 months of age [21] [22] [23] , and that tumour formation is markedly accelerated upon loss of one Trp53 allele (in Eµ-Myc; Trp53 +/− mice) 21 . Remarkably, we observed that the latency of tumour formation in Eµ-Myc mice (median tumour-free survival of ~220 d) is also dramatically reduced by the absence of one Alox12 allele (Eµ-Myc; Alox12 +/− mice; median survival of ~70 d) (Fig. 3d) . Of note, Eµ-Myc; Alox12 +/− mice presented with severe lymphadenopathy (Fig. 3e) and developed high-grade diffuse B cell lymphomas ( Fig. 3f) with a latency similar to that of Eµ-Myc; Trp53 +/− mice (median tumour-free survival of ~50 d), indicating that ALOX12-dependent ferroptosis contributes significantly to p53-mediated tumour suppression in the Eμ-Myc lymphoma model.
Although the lymphomas that arise in Eμ-Myc mice often exhibit defects in the ARF-p53 tumour suppression pathway [21] [22] [23] , neither the Arf (also known as Cdkn2a) nor the Trp53 gene was deleted or mutated in tumours derived from Eµ-Myc; Alox12 +/− mice (Fig. 3g) , which was further validated by sequencing analysis ( Supplementary  Fig. 4a ). Likewise, the major p53 feedback inhibitors, MDM2 and MDMX, were not overexpressed in these tumours (Fig. 3g) . Loss of functional Trp53 through the two-hit mechanism is among the most frequent events in human cancers and a 'loss of heterozygosity' deletion is often associated with tumour development 24 . Indeed, loss of heterozygosity deletions of the Trp53 gene were confirmed in tumours derived from Eµ-Myc; Trp53 +/− mice ( Fig. 3g and Supplementary Fig. 4a ). By contrast, however, loss of heterozygosity deletions of the Alox12 gene were not observed in tumours derived from Eµ-Myc; Alox12 +/− mice ( Fig. 3g and Supplementary Fig. 4b ). Notably, the levels of Ptgs2 and Chac1, two known markers of ferroptosis, were significantly downregulated in the tumours of Eµ-Myc; Alox12 +/− mice relative to the tumours of Eµ-Myc control mice (Fig. 3h) ; by contrast, the levels of p21 and p53 upregulated modulator of apoptosis (PUMA; also known as BBC3), two well-known markers of p53-mediated cell-cycle arrest and apoptosis, remained the same (Fig. 3g) , suggesting that loss of p53-dependent ferroptosis is the key event during tumour development. Indeed, inactivation of Alox12 had no obvious effect on p53-mediated cell-cycle arrest and apoptosis ( Supplementary Fig. 4c-e) . Taken together, these findings demonstrate that loss of one Alox12 allele is sufficient to accelerate Myc-induced tumorigenesis in a haploinsufficient manner even when the canonical functions of the p53 pathway in cell-cycle arrest and apoptosis remain intact.
ALOX12 missense mutations from human cancers abrogate ALOX12 enzymatic activity and p53-mediated ferroptosis. As Articles NATure CeLL BIOLOGy monoallelic loss of ALOX12 impairs both p53-mediated ferroptosis and p53-mediated tumour suppression, the above data indicate that ALOX12 itself functions as a haploinsufficient tumour suppressor.
Consistent with this notion, examination of the Oncomine database reveals that ALOX12 expression is downregulated in various human cancers, including cervical squamous cell carcinoma, ) and RSL-3 (1 µM) as indicated for 8 h. Mean ± s.d. is shown; n = 3 independent experiments. e, H1299 Tet-on p53 3KR control or ALOX12 CRISPR clones pre-incubated with doxycycline (0.5 µg ml 
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+/- +/− mice. Mean ± s.d. is shown; n = 3 independent experiments. The P values (c,h) were calculated using two-tailed unpaired Student's t-test; P value (Eµ-Myc versus Eµ-Myc; Alox12 +/− background) was calculated using the log-rank Mantel-Cox test. Detailed statistical tests are described in the Methods. Scanned images of unprocessed blots are shown in Supplementary Fig. 9 . Raw data are provided in Supplementary Table 1 .
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NATure CeLL BIOLOGy head and neck squamous cell carcinoma, oesophageal squamous cell carcinoma and acute myeloid leukaemia ( Supplementary  Fig. 5a,b) . In addition, several ALOX12 missense mutations are present in the COSMIC database of human tumour specimens, including R562Q/W (R→Q or W mutation at amino acid 562), A372T/D (A→T or D mutation at amino acid 372) and G381R (G→R mutation at amino acid 381) ( Fig. 4a and Supplementary Table 2 ). As the affected residues are evolutionally conserved and localized within the lipoxygenase domain ( Fig. 4a and Supplementary Fig. 5d ), these mutations may have functional consequence. To this end, we first examined the effects of these mutations on lipoxygenase activity. As shown in Fig. 4b , the wild-type ALOX12 protein readily oxidized arachidonic acid in vitro and, as expected, its lipoxygenase activity was inhibited by ML-355, a specific ALOX12 inhibitor 25 . Moreover, p53-mediated ferroptosis was blocked by ML-355 ( Supplementary Fig. 5e,f) . Notably, this lipoxygenase activity was significantly impaired by each of the tumourderived missense mutations tested (G381R, R562Q, R562W, A372T and A372D) (Fig. 4c) . Moreover, p53-mediated ferroptosis in ALOX12-null U2OS cells was restored by ectopic expression of wild-type ALOX12 but not by the tumour-derived ALOX12 G381R mutant ( Fig. 4d and Supplementary Fig. 5g ). Similar data were also obtained in ALOX12-null H1299 cells and further analysis showed that none of these tumour-derived mutants was able to fully induce cell death under the same conditions (Fig. 4e,f) . Taken together, these data demonstrate that the ALOX12 gene is downregulated and mutated in human cancers, and that tumour-derived ALOX12 missense mutations are defective in both lipoxygenase activity and the ability to induce p53-mediated ferroptosis.
Mechanistic insight into p53-mediated activation of ALOX12.
The specific requirement for ALOX12 in p53-dependent ferroptosis raised the possibility that ALOX12 activity may be regulated by p53. As no obvious effect on ALOX12 levels was detected upon p53 activation (Fig. 1d,g ), we examined whether ALOX12 function is modulated by known p53 targets involved in ferroptosis, such as SLC7A11. To this end, we first tested whether SLC7A11 interacts with ALOX12. As shown in Fig. 5a , ALOX12 (lane 4), but not ALOX15 (lane 8), readily co-immunoprecipitated with Flag-haemagglutinin (HA)-tagged SLC7A11. Indeed, none of other ALOX family members (ALOXE3, ALOX5, ALOX12B and ALOX15B) was detectable in the Flag-SLC7A11 immunoprecipitates ( Supplementary  Fig. 6a-d) , indicating that SLC7A11 interacts specifically with ALOX12. Purified SLC7A11 bound to a recombinant ALOX12 in an in vitro pull-down assay (Fig. 5b) , indicating that ALOX12 and SLC7A11 interact directly. Moreover, co-immunoprecipitation analysis confirmed that the endogenous ALOX12 and SLC7A11 polypeptides also interact in vivo (Fig. 5c) . Together, these data demonstrate that ALOX12 is a bona fide binding partner of SLC7A11.
To elucidate the functional consequence of this interaction, we tested whether SLC7A11 affects ALOX12 lipoxygenase activity. As shown in Fig. 5d ,e, the lipoxygenase activity of ALOX12, but not of ALOX15, was suppressed in a dosage-dependent manner by SLC7A11 expression (Supplementary Fig. 6e,f) . Although the protein structure of SLC7A11 has not yet been solved, it is predicated as a 12-pass transmembrane protein with several domains located inside the cell 26 . Further analyses demonstrate that the intracellular loop of SLC7A11 (amino acids 98-131) plays a key role in binding and repressing ALOX12 lipoxygenase activity ( Supplementary  Fig. 6h-j) . As SLC7A11 levels are downregulated by p53, this observation suggested that p53 can promote ALOX12 function indirectly by downregulating SLC7A11. Indeed, as shown in Fig. 5f , SLC7A11 levels were reduced (right panel) and ALOX12 activities were elevated (left panel) in human U2OS cells upon Nutlin-induced p53 activation. Together, these data demonstrate that (1) SLC7A11 specifically binds to and inhibits the enzymatic activity of ALOX12 and (2) p53 induces ALOX12 lipoxygenase activity by repressing SLC7A11 expression.
ALOX12 is dispensable for ferroptosis induced by erastin or GPX4 inhibitors. To elucidate differences between p53-mediated and erastin-induced ferroptosis, we first examined the effect of erastin on ALOX12 function. Erastin treatment did not affect the interaction between SLC7A11 and ALOX12 (Fig. 5g) or the levels of ALOX12 activity (Fig. 5h) . In contrast to p53-mediated ferroptosis, erastin-induced ferroptosis was not significantly affected in isogenic Alox12
+/-and Alox12 -/-MEFs ( Fig. 5i and Supplementary  Fig. 7a ) or ALOX12-null U2OS cells ( Supplementary Fig. 7b,c) .
Together, these data demonstrate that ALOX12 is not required for erastin-induced ferroptosis.
Thus, although p53 and erastin both induce ferroptosis by targeting the same factor (SLC7A11), the mechanisms are strikingly different, as exemplified by the fact that p53 is ALOX12 dependent, whereas erastin is ALOX12 independent. On the one hand, p53 promotes ferroptosis through transcriptional repression of SLC7A11, which in turn releases the lipoxygenase activity of ALOX12 from SLC7A11 inhibition. On the other hand, although erastin suppresses the antiporter activity of SLC7A11 (ref. 27 ), it fails to abrogate SLC7A11 inhibition of ALOX12. Nevertheless, erastin treatment ultimately induces ferroptosis by blocking cystine import, GSH biosynthesis and GPX4 activity 7, 8 . Indeed, most of the described ferroptotic responses, including that induced by erastin, entail inhibition of GPX4 (refs. [8] [9] [10] 19 ). In this regard, we also found that loss of ALOX12 expression has no obvious effect on ferroptosis induced by RSL-3, a specific GPX4 inhibitor (Supplementary Fig. 7d) . Thus, the mechanism of p53-dependent ferroptosis is distinct from that of ferroptotic responses induced by erastin or GPX4 inhibitors.
ACSL4 is required for ferroptosis induced by erastin or GPX4 inhibitors but is dispensable for p53-mediated ferroptosis.
Recent studies show that the ferroptotic responses induced by either erastin or GPX4 inhibitors are dependent on acyl-CoA synthetase long-chain family member 4 (ACSL4), an enzyme that promotes biosynthesis of unsaturated phospholipids, the main substrates for lipid peroxidation 28, 29 . To further elucidate the mechanism of p53-mediated ferroptosis, we generated ACSL4-knockout cell lines of U2OS (Fig. 6a) . As expected, ACSL4-null cells are resistant to ferroptosis induced by either erastin (Fig. 6b) or the GPX4 inhibitor RSL-3 (Fig. 6c) . By contrast, however, ACSL4-null cells are fully susceptible to p53-mediated ferroptosis (Fig. 6d) . Moreover, we generated Acsl4-mutant mice ( Supplementary Fig. 8a-c) and obtained Acsl4 -/-MEFs for ferroptotic analysis. As expected, the ACSL4 protein was not detectable in Acsl4 -/-MEFs (Fig. 6e ) and the levels of ferroptosis induced by erastin (Fig. 6f) or RSL-3 (Fig. 6g) were largely suppressed. Again, however, p53-dependent ferroptosis was fully retained in Acsl4 -/-MEFs (Fig. 6h) . Together, these data demonstrate that p53-mediated ferroptosis is ALOX12 dependent but ACSL4 independent.
p53-mediated ferroptosis is deregulated in human cancer cell lines expressing wild-type p53. To examine whether p53-mediated ferroptosis is deregulated in human cancers, we examined ALOX12 protein levels in numerous human cancer cell lines that retain wildtype p53. As shown in Fig. 7a, ALOX12 was undetectable in the human fibrosarcoma cell line HT1080, the original cell line characterized for erastin-induced ferroptosis 7 . As expected, ferroptosis was readily induced in the cells by erastin (Fig. 7c) . By contrast, HT1080 cells were not susceptible to p53-mediated ferroptosis (Fig. 7d, left  panel) , despite the fact that SLC7A11 levels were downregulated upon p53 activation (Fig. 7b) . However, these cells were rendered susceptible to p53-mediated ferroptosis by ectopic expression of ALOX12 (Fig. 7d) . Similar results were also obtained in the human ) and TBH (60 µM) as indicated for 8 h. Scale bars, 100 µm. The experiments were repeated twice, independently, with similar results. f, The cell death of H1299 Tet-on p53 3KR ALOX12 CRISPR cells transfected with control or ALOX12 vectors from e as indicated. Mean ± s.d. is shown; n = 3 independent experiments. All P values (b,c,f) were calculated using two-tailed unpaired Student's t-test. Detailed statistical tests are described in the Methods. Scanned images of unprocessed blots are shown in Supplementary Fig. 9 . Raw data are provided in Supplementary +/− and Alox12 −/− MEFs were treated with erastin (10 µM) and Ferr-1 (2 µM) for 12 h. Mean ± s.d. is shown; n = 3 independent experiments. All P values (d-f,h,i) were calculated using two-tailed unpaired Student's t-test. Detailed statistical tests are described in the Methods. Scanned images of unprocessed blots are shown in Supplementary Fig. 9 . Raw data are provided in Supplementary Table 1 .
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NATure CeLL BIOLOGy colorectal cancer cell line HCT116 (Fig. 7e, left panel) . Of note, it was recently reported that p53-induced ferroptosis was not observed in HCT116 and HT1080 cell lines; instead, p53 stabilization led to repression of erastin-induced ferroptosis in these cells 30, 31 , further validating the specific role of ALOX12 in p53-mediated ferroptosis. Notably, ACSL4 is not expressed in the human breast cancer cell −/− MEFs treated with erastin (10 µM) and Ferr-1 (2 µM) as indicated for 9 h. Quantification of cell death is shown; mean ± s.d.; n = 3 independent experiments, except for ctrl n = 9. g, WT and Acsl4 −/− MEFs treated with RSL-3 (1 µM) and Ferr-1 (2 µM) as indicated for 9 h. Quantification of cell death is shown; mean ± s.d.; n = 3 independent experiments except for ctrl n = 9. h, WT and Acsl4 −/− MEFs pre-incubated with Nutlin (10 µM) for 12 h were treated with TBH (80 µM) and Ferr-1 (2 µM) as indicated for 9 h. Quantification of cell death is shown; mean ± s.d.; n = 3 independent experiments. All P values (b-d,f-h) were calculated using two-tailed unpaired Student's t-test. Detailed statistical tests are described in the Methods. Scanned images of unprocessed blots are shown in Supplementary Fig. 9 . Raw data are provided in Supplementary Table 1.
NATure CeLL BIOLOGy line MCF-7 (Fig. 7a, lane 7) and, indeed, these cells are resistant to both erastin-mediated (Fig. 8a) and RSL-3-mediated (Fig. 8b) ferroptosis. Nonetheless MCF-7 cells are clearly susceptible to p53-mediated ferroptosis induced by ROS stress (Fig. 8c) . Moreover, p53-mediated ferroptosis was also readily detected in other cell lines in which both p53 and ALOX12 are expressed, including the human lung carcinoma lines A549 and H460 and the human melanoma line A375 (Fig. 8d-f) . As expected, p53-mediated ferroptosis in these cells was completely suppressed by the ALOX inhibitor ML-355 (Fig. 8d-f) , further validating the specific requirement for ALOX12 in p53-mediated ferroptosis.
Discussion
Although the precise mechanisms by which p53 induces ferroptosis still require further elucidation, our study emphasizes the importance of ROS in this process. In addition to treatment with TBH, p53-mediated ferroptosis can also be induced by other forms of ROS, such as low levels of hydrogen peroxide (H 2 O 2 ) and paraquat ( Fig. 8g and Supplementary Fig. 8d ). Thus, p53 promotes tumour suppression at least in part by sensitizing cancer cells to ferroptotic death upon oxidative stress. As high levels of cell proliferation are generally accompanied by increased ROS production, cancer cells are likely to select for various strategies, such as SLC7A11 +/+ cells transfected with ALOX12 is also shown (right panel). The western blot experiment was repeated twice, independently, with similar results. All P values (c-e) were calculated using two-tailed unpaired Student's t-test. Detailed statistical tests are described in the Methods. Scanned images of unprocessed blots are shown in Supplementary Fig. 9 . Raw data are provided in Supplementary Table 1 .
Articles NATure CeLL BIOLOGy overexpression or ALOX12 inactivation, to protect themselves from ROS-induced ferroptosis.
The ALOX12 gene resides on human chromosome 17p13.1 at a position very close to the TP53 locus (Supplementary Fig. 8e ). As loss of one copy of chromosome 17p13.1 is very common in human cancer, it is likely that many human tumours have lost one allele of ALOX12 (refs. 24, [32] [33] [34] . Interestingly, recent studies indicate that a substantial fraction (31-36%) of human tumours containing chromosome 17p deletion retain a wild-type TP53 allele 24 . In light of our data that ALOX12 haploinsufficiency inhibits p53-mediated ferroptosis and accelerates Myc-induced tumorigenesis without obvious alterations in the ARF-p53 pathway, it Nutlin: Ferr-1: ; n = 3 independent experiments. e, H460 cells pre-incubated with Nutlin (10 µM) for 12 h were treated with TBH (300 µM), Nutlin (10 µM), ML-355 (4 µM) and Ferr-1 (2 µM) as indicated for 8 h. Quantification of cell death is shown; mean ± s.d.; n = 3 independent experiments. f, A549 cells pre-incubated with Nutlin (10 µM) for 12 h were treated with TBH (150 µM), Nutlin (10 µM), ML-355 (4 µM) and Ferr-1 (2 µM) as indicated for 8 h. Quantification of cell death is shown; mean ± s.d.; n = 3 independent experiments. g, U2OS cells pre-incubated with Nutlin (10 µM) for 12 h were treated with Nutlin (10 µM), H 2 O 2 (100 µM), Ferr-1 (2 µM) and ML-355 (4 µM) as indicated for 48 h. The percentage of cell death is shown; mean ± s.d.; n = 3 independent experiments. h, A model of p53-mediated ferroptosis compared to erastin-induced ferroptosis. PUFAs, polyunsaturated fatty acids. All P values (a-g) were calculated using two-tailed unpaired Student's t-test. Detailed statistical tests are described in the Methods. Raw data are provided in Supplementary Table 1 .
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NATure CeLL BIOLOGy is conceivable that monoallelic loss of ALOX12 is an aetiological factor in this subset of patients. Notably, in contrast to the severe phenotypes associated with GPX4-mutant mice [12] [13] [14] [15] [16] [17] 35 , deletion of the Alox12 gene does not elicit major developmental defects in mice 36 . Thus, ALOX12, in a manner reminiscent of p53, is largely dispensable for most developmental processes that entail ferroptosis. As ALOX12 is deleted, downregulated and mutated in human cancers, the p53-ALOX12 axis may act as a potential barrier to cancer development.
Although numerous studies implicate GPX4 inhibition as a central node for the induction of ferroptosis, our data identify a distinct mechanism through which p53 induces the ferroptotic response. In particular, we found that p53 is able to activate ALOX12 function indirectly by transcriptional repression of SLC7A11, resulting in ALOX12-dependent ferroptosis upon ROS stress (Fig. 8h) . Further investigations are needed to examine whether other metabolic targets of p53 also contribute to ALOX12 activation [2] [3] [4] [5] . Notably, in contrast to the effects by erastin treatment, we observed that p53 activation alone by Nutlin treatment does not significantly induce downregulation of the GSH/GSSG ratio, GSH levels and GPX4 activity in human cancer cells (Fig. 2a,b,d ). Although downregulation of SLC7A11 induced by p53 is able to partially inhibit cystine uptake 3 , the overall effects on the GSH/GSSG ratio and GSH levels are apparently neutralized, probably by activation of other p53 targets, such as TIGAR (TP53-inducible glycolysis and apoptosis regulator) and p21. For example, activation of TIGAR by p53 was found to reduce ROS levels and increase the GSH/GSSG ratio 37, 38 ; p53-mediated activation of p21 was reported to promote the conservation of GSH 30 . Our data have further demonstrated that ALOX12-mediated ferroptosis is independent of ACSL4 (Fig. 8h) . As ACSL4 is required for ferroptosis induced by erastin or GPX4 inhibitors 28, 29 , our study reveals a previously uncovered ferroptotic pathway, distinct from the current ferroptosis model mainly focusing on GPX4 modulation.
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Methods
Cell culture and stable lines. U2OS, H1299, A549, A375, MCF-7, HCT116, HT1080, H460 and SJSA cancer lines were obtained from the American Type Culture Collection (ATCC) and have been proven to be negative for mycoplasma contamination. No cell lines used in this work were listed in the ICLAC database. All cells were cultured in a 37 °C incubator with 5% CO 2 . All media used for cancer cells were supplemented in DMEM with 10% FBS, 100 U ml −1 penicillin and 100 µg ml −1 streptomycin (all from Gibco). MEFs were generated from day 13.5 embryos and supplemented in DMEM with 10% heat-inactivated FBS, 100 U ml −1 penicillin, 100 µg ml −1 streptomycin and 1% non-essential amino acids. H1299 Tet-on p53 3KR cells were previously described (Jiang et al. 3 ). To obtain ALOX12, CRISPR-Cas9-knockout U2OS and H1299 Tet-on p53 3KR cells were generated by transfecting a ALOX12 double nickase plasmid (sc-403010-NIC; Santa Cruz). The cells were selected with puromycin (1 µg ml
) for 4-6 d. ALOX12-knockout single clones were then screened and acquired after continuing to culture 2-3 weeks without selective antibiotics. Identical strategies were used to generate ALOX15-knockout, p53-knockout and ACSL4-knockout cells (ALOX15, sc-401591-NIC; p53, sc-416469-NIC; and ACSL4, sc-401649-NIC). To generate the ALOX12 stable cell line, wild-type or mutant pcin4-Flag-HA-ALOX12 was transfected into U2OS cells, followed by selection and maintenance with 1 mg ml −1 G418 (Sigma) in DMEM medium containing 10% FBS. Single clones were selected and screened by western blot.
Plasmids. The pcDNA-ALOX12 plasmid was generously gifted from C. D. Funk (Queen's University, Kingston, Ontario, Canada). For wild-type ALOX12, full-length ALOX12 was subcloned into the pcDNA3.1/v5-His-Topo vector (Invitrogen), and mutant ALOX12 Topo plasmids were constructed using the QuickChange XL Site-Directed Mutagenesis Kit (Agilent) according to the standard protocol. For Flag-HA wild-type and mutant ALOX12, full-length ALOX12 was subcloned into the pcin4-Flag-HA vector. For Flag-HA-SLC7A11, full-length SLC7A11 was subcloned into the pcin4-Flag-HA vector. For V5-ALOXe3, ALOX5, ALOX12, ALOX12B, ALOX15 and ALOX15B, full-length ALOXs were subcloned into the pcDNA3.1/v5-His-Topo vector.
Western blotting and antibodies. Protein extracts were analysed by western blotting according to standard protocols using primary antibodies against p53 (DO-1; sc-126; Santa Cruz; 1:1,000 dilution), p53 (FL-393; sc-6243; Santa Cruz; 1:1,000 dilution), MDM2 (Ab-5) mouse monoclonal antibody (4B2C1.11; OP-145; Millipore; 1:100 dilution), p21 (SX118; sc-53870; Santa Cruz; 1:1,000 dilution), MDMX (A300-287A; Bethyl; 1:1,000 dilution), p19-ARF antibody (5C-3; ab-26696; Abcam; 1:1,000 dilution), PUMA antibody (H-136; sc-28226; Santa Cruz; 1:500 dilution), SLC7A11 antibody (D2M7A; 12691s; Cell Signaling; 1:500 dilution), ACSL4 antibody (A5; sc-271800; Santa Cruz; 1:1,000 dilution), V5 (R960-25; Invitrogen; 1:1,000 dilution), HA (11867423001; Sigma; 1:1,000 dilution), ALOX12 antibody (C-5; sc-365194; Santa Cruz; 1:200 dilution), ALOX15 (ab-80221; Abcam; 1:1,000 dilution) and vinculin (V9264; Sigma-Aldrich; 1:5,000 dilution). Horseradish peroxidase-conjugated anti-mouse and anti-rabbit secondary antibody (GE Healthcare) and anti-rat (Southern Biotech) were used. More detailed information is provided in Supplementary Table 3 . 
RNA extraction and quantitative RT-PCR and sequencing of tumour samples.
Total RNA was extracted using TRIzol (Invitrogen) according to the manufacturer's protocol. cDNA was reversed using SuperScript IV VILO Master Mix (Invitrogen). For the quantitative RT-PCR analysis of human transcripts, the following primers were used: PTGS2 forward 5′-CTTCACGCATCAGTTTTTCAAG-3′, PTGS2 reverse 5′-TCACCGTAAATATGATTTAAGTCCAC-3′; ALOX15 forward 5′-AGCCTGATGGGAAACTCTTG-3′, ALOX15 reverse 5′-AGGTGGTGGG GATCCTGT-3′; ALOXe3 forward 5′-GTGGATTGAAGGCTACTGCAC-3′, ALOXe3 reverse 5′-GGGGAAGAGAGTCCTGACAA-3′; ALOX5 forward 5′-TTTCATCGTGGACTTTGAGC-3′, ALOX5 reverse 5′-ATCTTGTTGGC CAGGTTCTT-3′; ALOX12 forward 5′-GAGGAATTTTTGATAAGGCAGTG-3′, ALOX12 reverse 5′-CCCGACGGAGCAACTGTA-3′; ALOX12B forward 5′-GA CACTTCCCGGACATTCAC-3′, ALOX12B reverse 5′-GGAACGCCTCTATG CTCCT-3′; ALOX15B forward 5′-GATCTTCAACTTCCGGAGGAC-3′; ALOX15B reverse 5′-ACTGGGAGGCGAAGAAGG-3′; and GAPDH forward 5′-ATCAATGG AAATCCCATCACCA-3′, GAPDH reverse 5′-GACTCCACGACGTACTCAGCG-3′.
For RT-PCR: mouse full-length Trp53 forward 5′-CCCTCCCACGTGC TCACCCTG-3′, Trp53 reverse 5′-CTCAGAGAGGGGGCTGAGCTAC-3′. For Alox12 genotyping: mouse Alox12 wild-type 5′-CCTCAGTGCAGGAACCTG TG-3′, Alox12 mutant 5′-TACTTCCATTTGTCACGTCCTG-3′ and the common primer for wild-type and mutant Alox12 5′-CTGCTACCCATGGCTATCCAG-3′.
Cell death assay. For p53-dependent ferroptosis, we used the assay established in our previous study 3 , showing a ferroptotic response that requires both p53 activation and ROS stress, generated by low levels of TBH. The ROS generator TBH, which is converted into peroxyl and alkoxyl radicals by cytochrome P450 (ref. 39 ), is more stable than traditional oxidative reagents, such as H 2 O 2 (refs. 40, 41 ). Although high levels of TBH treatment may induce different types of cell death, no significant cell death was observed under low levels of TBH treatment 3 . Nevertheless, the combination of low levels of TBH treatment and p53 activation (for example, Nutlin treatment) is able to induce ferroptosis. Typically, careful titration is performed to determine the concentration of TBH as well as the incubation time for p53-dependent ferroptosis on specific cell lines used. Similar assays with TBH treatment for ferroptosis were also reported by others 6, 9 . Cells were trypsinized, collected and stained with trypan blue and then counted with a haemocytometer using a cell number counter (Life Technologies countess II). Living and dead cells were all counted according to the cell size, and cells stained blue were considered as dead cells. The cell death assays were also further confirmed by FACS with similar results. To validate whether these are ferroptotic cell death, we treated the cells with Ferr-1 or other cell death inhibitors. If the cell death can be completely rescued by Ferr-1 but not by other cell death inhibitors, the cell death is ferroptotic.
Drugs and inhibitors.
For ROS generation, TBH (Sigma) was used at different doses depending on the experiment; see respective figure legends. A specific GPX4 inhibitor (B6095; APExBIO) was used. A specific cell death inhibitor and ALOX12 activity inhibitor were used in the experiments: Ferr-1 (ferroptosis inhibitor; Xcess Biosciences) and ML-355 (ALOX12 inhibitor; Cayman Chemical) were used at different doses depending on the experiment; see respective figure legends.
Expression, purification and activity assay of ALOX12 in vitro. For purification of ALOX12 proteins from U2OS cells, U2OS cells were transfected with pCIN4-Flag-HA-ALOX12 and grown for 24 h. Then, the cells were harvested and lysed using BC100 buffer (20 mM Tris-HCl, pH 7.3, 100 mM NaCl, 10% glycerol, 0.2 mM EDTA, 1% NP-40 and proteinase inhibitor, with a final concentration of 0.1 mM TPP (triphenylphosphine) on ice for 1 h. The cell lysate was centrifuged for 15 min at 15,000 r.p.m. at 4 °C. The supernatants were used for Flag/M2 immunoprecipitations by anti-Flag antibody-conjugated agarose (Sigma) and incubated overnight. The bound ALOX12 proteins were eluted with 10 µg ml −1 Flag peptide (Sigma) in BC100 solution.
Considering that arachidonic acid is a substrate of ALOX12, active ALOX12 will metabolize arachidonic acid into 12-hydroxyeicosatetraenoic acid (12-HETE). Specifically, active ALOX12 reduces 12(S)-hydroperoxy tetraenoic eicosatetraenoic acid (12(S)-HpETE) into 12-HETE. The amount of 12-HETE can be measured by enzyme-linked immunosorbent assay (ELISA). Thus, for the ALOX12 catalytic activity assay, aliquots of the purified ALOX12 enzyme (500 ng) were incubated with arachidonic acid (100 µM) for 10 min in PBS containing 0.1 mM ATP (New England Biolabs) and 0.4 mM Ca 2+ with or without 4 µM ML-355 (as in Fig. 4b ). Then, the reaction solution was acidified with acetic acid to a pH of approximately 3-4 as determined by standard pH paper. The samples were extracted with equal volume ethyl acetate and then dried and dissolved in 20 µl ethanol.
To detect 12-HETE levels, we performed a 12-HETE ELISA. Purified 12-HETE (100 µl) was used to generate a serial dilution for the standard curve (1 mg ml −1 ; Detroit R&D). The samples from the purified ALOX12 reaction buffer were diluted to 500 µl with a 1× sample dilution buffer.
Then, 100 µl of each of the 12-HETE standards (from 1,000,000 pg ml −1 to 10 pg ml
) and the reaction samples were loaded into a 96-well plate coated with anti-12-HETE antibody (Detroit R&D). Next, the 12-HETE-horseradish peroxidase conjugate was added to each well and the plate was incubated at room temperature for 2 h. The plate was washed three times after incubation and 200 µl TMB (3,3′,5,5′-tetramethylbenzidine) substrate was added to all of the wells and incubated for 15-30 min, then the reaction was stopped with 50 µl 2 N sulfuric acid and the plate was read at 450 nm.
Measurement of GSH in vivo.
To measure total GSH and the ratio of reductive GSH to oxidative GSH, we used the GSSG/GSH quantification kit (Donjindo Molecular Technologies). U2OS cells were collected and washed with PBS. The cells were lysed by freezing and thawing twice upon the addition of 10 mM HCl. The cells were then added in 5% 5-sulfosalicylic acid and centrifuge at 8,000g for 10 min. The supernatants with a final concentration of 0.5% 5-sulfosalicylic acid were used for the assays. To detect GSH levels, GSH standard solution was used to generate a serial dilution for the standard curve (200 µM).
Then, 40 µl GSH and GSSG standard solution and samples were loaded into a 96-well plate. Next, 60 µl buffer solution was added to each well and the plate was incubated at 37 °C for 1 h. Substrate working solution (60 µl) was added to each well and subsequently with 60 µl enzyme/coenzyme working solution, incubated at 37 °C for 10 min and the plate was read at 405 nm.
Measurement of GPX4 activity in vivo.
To measure GPX4 activity, we used the GSH peroxidase assay kit (Abcam). The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
The statistical test(s) used AND whether they are one-or two-sided
Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted 
Data analysis
Data quantification were performed with Excel, Image J and CellQuest and statistical analysis with Excel and GraphPad Prism V6. Images were processed with Adobe Photoshop.
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The ALOX12 gene expression data for normal versus cancer human tissues were derived from Oncomine database(https://www.oncomine.org/resource/). Source data for Figs. 1a,c,f, 2a-b, d-e,g, 3c-d,h, 4b-c,f, 5d-f,h-i, 6b-d,f-h, 7c-e and 8a-g and Supplementary Figs. 1b,d -e, 2b, 3b-d, 5c-d, 6j,7a-c and 8d have been provided as Supplementary Table 1 . All other data supporting the findings of this study are available from the corresponding author on reasonable request.
